stockrowHCW Biologics Inc.
HCWB Healthcare Biotechnology
HCW Biologics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $54,200.00, down 97.9% from fiscal 2024.
- Revenue
- +1,954.6%
- EPS
- +71.6%
- Free cash flow
- −20.8%
- Total debt
- −3.34%
Quarter to June 2026, against a year earlier
Follow HCWB
Alert me
HCW Biologics Inc. (HCWB) EV/Sales
As of 6 November 2026, HCW Biologics Inc. (HCWB) trades at a EV/Sales of 1.1×. Over the past ten years it has ranged from 0.0× (December 2022) to 638× (April 2024); the current reading is higher than 28% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 134× | 1,203.26% |
| FY2024 | 10.3× | (36.58%) |
| FY2023 | 16.2× | 143.92% |
| FY2022 | 6.6× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.9× | 63.90% |
| Mar 2026 | 1.2× | (99.13%) |
| Dec 2025 | 134× | 290.77% |
| Sep 2025 | 34.2× | 149.62% |
| 14 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| VIVS VivoSim Labs, Inc. compare | −8.4× |
| BRTX Biorestorative Therapies, Inc. compare | −5.8× |
| EOCN Eocene Ltd. compare | −3.1× |
| APVO Aptevo Therapeutics Inc. compare | −0.4× |
| CLDI Calidi Biotherapeutics, Inc. compare | n/m |
| SLXN Silexion Therapeutics Corp compare | n/m |
| HCWB HCW Biologics Inc. | 1.1× |
| WINT Windtree Therapeutics, Inc. compare | 63.8× |
| BIORQ Biora Therapeutics, Inc. compare | 67.4× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)